The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down

Becton, Dickinson and Company (NYSE:BDX ) Q1 2023 Earnings Conference Call February 2, 2023 8:00 AM ET Company Participants Francesca DeMartino – Senior Vice President and Head-Investor Relations Tom Polen – Chairman, Chief Executive Officer and President Chris DelOrefice – Executive Vice President and Chief Financial Officer Dave Hickey – President-Life Sciences Segment Mike Garrison – President-Medical Segment Conference Call Participants Vijay Kumar – Evercore ISI Matt Taylor – Jefferies Larry Biegelsen – Wells Fargo Robbie Marcus – JPMorgan Matt Miksic – Barclays Rick Wise – Stifel Operator Hello, and welcome to BD's First Fiscal Quarter of 2023 Earnings Call. At the request of BD, today's call is being recorded, and a replay of the call will be made available on BD's Investor Relations website on bd.com.

Becton, Dickinson and Company (BDX) Q1 2023 Earnings Call Transcript

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.61% and 0.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates

Becton Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Becton Dickinson (BDX) Ahead of Earnings?

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Becton Dickinson (BDX) Could Beat Earnings Estimates Again

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.